Adicet Bio (ACET) vs Marker Therapeutics (MRKR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Marker Therapeutics (MRKR) has outperformed Adicet Bio (ACET) over the past year, gaining 2.8% versus a loss of 77.8%. Over five years, MRKR leads with a -91.1% price change compared with -98.6% for ACET. Adicet Bio is the larger company by market cap ($20.0 million vs $18.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACET | MRKR |
|---|---|---|
| Share price | $2.14 | $1.09 |
| Market cap | $20.03M | $18.17M |
| 1-day change | -13.01% | -17.42% |
| YTD return | -74.58% | -26.85% |
| 1-year return | -77.78% | +2.83% |
| 5-year return | -98.58% | -91.14% |
| EPS (TTM) | $-7.53 | $-0.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $3.55M |
| Revenue growth (YoY) | — | -46.19% |
| Net income (latest FY) | $-116.80M | $-12.16M |
| Operating margin | — | -363.45% |
| Net margin | — | -342.96% |
| 52-week high | $11.15 | $2.46 |
| 52-week low | $2.12 | $0.81 |
| Distance from 52-week high | -80.81% | -55.69% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1527.57% | +622.02% |
| Average volume | 271.05K | 711.96K |
| Shares outstanding | 9.36M | 16.67M |
| Employees | 102 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRKR has outperformed ACET by 80.6 percentage points over the past year.
About Adicet Bio
ACET stock →Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees
About Marker Therapeutics
MRKR stock →Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
ACET vs MRKR FAQ
Which is bigger, Adicet Bio or Marker Therapeutics?
Adicet Bio (ACET) is larger, with a market capitalization of $20.03M compared with $18.17M for Marker Therapeutics (MRKR).
Which stock has performed better over the past year, ACET or MRKR?
MRKR returned +2.83% over the past 12 months, compared with -77.78% for ACET (price return, excluding dividends). Past performance does not predict future results.
Are Adicet Bio and Marker Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.